ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ENB Therapeutics to Present at SVB Securities Biopharma Private Company Connect on July 20-21, 2022

NEW YORK, NY / ACCESSWIRE / July 14, 2022 / ENB Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today announced that Sumayah Jamal, MD-PhD, President, Co-Founder, and CSO of ENB Therapeutics, will be participating in the SVB Securities Biopharma Private Company Connect to be held virtually on July 20th and 21st. The ENB team will meet with investors in one-on-one meetings, which can be requested through SVB, and will present a corporate overview. For more information please see: https://www.svbsecurities.com/events/

About ENB Therapeutics, Inc.

ENB Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, endothelin B receptor (ETBR) inhibitors, to overcome resistance to immune-based therapies such as the immune checkpoint inhibitors. ETBR causes uncontrolled cancer growth, drives cancers to spread through the body and prevents the immune system from detecting and killing cancer cells. ENB's lead product candidate, ENB-003 specifically blocks the ETBR and has the potential to enhance the efficacy of immune-based therapies. ENB-003 is currently being investigated in an ongoing Phase 1/2 clinical trial in collaboration with Merck.

Investor and Media Contact:
ENB Therapeutics, Inc.
Sumayah Jamal, MD-PhD
President, Co-Founder, CSO
info@enbpharma.com
Tel: (212)792-2317

SOURCE: ENB Therapeutics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708482/ENB-Therapeutics-to-Present-at-SVB-Securities-Biopharma-Private-Company-Connect-on-July-20-21-2022

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.